Sensifree

Company Overview

Snapshot

Founded in March 2012 by Eran Agmon and Ilan Barak, Sensifree operates with 1–10 employees. The company has raised $5 million across one funding round from three investors. In May 2016, Sensifree secured funding from investors including UMC Capital.

Business overview

Sensifree is focused on developing advanced blood pressure monitoring devices, providing cuff-free, comfortable, and discreet continuous monitoring of vital signs. The company utilizes proprietary RF-based technology to generate unique signals from the radial artery, enabling the evaluation of systolic and diastolic pressures. Sensifree aims to transform hypertension diagnosis and management, targeting clinics, home healthcare, and hospitals, with plans to expand into consumer healthcare and bedside patient monitoring. It operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices, with a focus on patient remote monitoring and medical monitors.

Strategic signal

In January 2018, Sensifree reported statistically significant concordance of its arterial pressure signal waveform between its continuous non-invasive blood pressure monitoring technology and invasive arterial line measurements. This validation of its core technology demonstrates the potential for its contactless heart rate monitoring solution to provide accurate and reliable data, signaling a strong foundation for clinical adoption and market expansion in the health tech and life sciences sector.

Company Intelligence Q&A

What is Sensifree's core technology?

Sensifree develops proprietary RF-based technology to generate unique signals from the radial artery for contactless and continuous monitoring of blood pressure and heart rate. This technology allows for cuff-free, comfortable, and discreet vital sign monitoring.

When was Sensifree founded and by whom?

Sensifree was founded in March 2012 by Eran Agmon and Ilan Barak.

What significant funding did Sensifree receive?

In May 2016, Sensifree raised $5 million in a funding round from investors UMC Capital.

What was a key technological validation for Sensifree?

In January 2018, Sensifree reported statistically significant concordance of its arterial pressure signal waveform between its continuous non-invasive blood pressure monitoring technology and invasive arterial line measurements, validating its core technology.

Has Sensifree formed any strategic partnerships?

In August 2020, Sensifree partnered with Dreamtech on product development, supported by the KORIL-RDF Foundation.